7c4477a6-c744-412a-8571-bfb62f0dc714
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 33.1635865845311
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.450
- E2F_TARGETS+0.450
- G2M_CHECKPOINT+0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- MYC_TARGETS_V2+0.370
- MYC_TARGETS_V1+0.320
- INTERFERON_ALPHA_RESPONSE+0.300
- IL6_JAK_STAT3_SIGNALING+0.290
- INFLAMMATORY_RESPONSE+0.280
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.370
- PEROXISOME-0.320
- BILE_ACID_METABOLISM-0.310
- PROTEIN_SECRETION-0.290
- ESTROGEN_RESPONSE_LATE-0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.280
- XENOBIOTIC_METABOLISM-0.280
- PI3K_AKT_MTOR_SIGNALING-0.240
- ESTROGEN_RESPONSE_EARLY-0.220
- FATTY_ACID_METABOLISM-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-98-8023-01A-11R-2247-07 | — | cohortSQ1 | 0.860 |
| 2 | TCGA-BH-A18V-01A-11R-A12D-07 | — | E | 0.834 |
| 3 | TCGA-A2-A0SX-01A-12R-A084-07 | — | D | 0.822 |
| 4 | TCGA-85-A511-01A-21R-A262-07 | — | cohortSQ1 | 0.822 |
| 5 | TCGA-AQ-A04J-01A-02R-A034-07 | — | D | 0.818 |
| 6 | C3L-04071 | — | cohortSQ1 | 0.816 |
| 7 | TCGA-AO-A0J4-01A-11R-A034-07 | — | E | 0.810 |
| 8 | SRR975554 | — | — | 0.797 |
| 9 | SRR650184 | — | — | 0.795 |
| 10 | 02fde1b1-c95c-4d8f-b57b-355b55072108 | — | — | 0.793 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |